The JPMorgan price target of $100 is a bit less than the $101.11 consensus target.
Monday, August 17, 2015
PTC Therapeutics Inc. (NASDAQ: PTCT)
PTC Therapeutics Inc. (NASDAQ: PTCT) is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology referred to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA is copied from DNA through the transcription process. PTC’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases.
The JPMorgan team recently upgraded the stock as they feel that, based on physician feedback and increased confidence in the Phase 3 ACT DMD study for Translarna in Duchenne muscular dystrophy, which they believe may be released in October, the stock holds a positive risk-reward profile into the clinical data release.
The JPMorgan price target of $100 is a bit less than the $101.11 consensus target.
The JPMorgan price target of $100 is a bit less than the $101.11 consensus target.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment